Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Revenues (Details 3)

v3.19.1
Revenues (Details 3)
₪ in Thousands
 12 Months Ended
Dec. 31, 2018
ILS (₪)
Revenues [Abstract]  
Beginning balance
Contract liability recognized due to LB agreement 7,346
Revenue recognized during the period (37)
End Balance 7,309 [1]
Contract liability presented in current liabilities 3,636
Contract liability presented in non-current liabilities ₪ 3,673 [2]
[1] Represents the unfulfilled performance obligation related to First BioInk.
[2] As of December 31, 2018, non-current contract liabilities are estimated to be recognized in 2020.